Ainos Inc AIMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AIMD is a good fit for your portfolio.
News
-
Ainos Reports First Quarter 2024 Financial Results
-
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
-
Ainos Reports Full Year 2023 Financial Results
-
Thinking about buying stock in Senseonics Holdings, Ainos, Marpai, Rush Street Interactive, or Evgo?
-
Thinking about buying stock in SoundHound AI, Macy's, Ainos, Helius Medical Technologies, or Renalytix?
-
Thinking about buying stock in MMTec, Ainos, Jumia Technologies, Akero Therapeutics, or BioVie?
Trading Information
- Previous Close Price
- $1.05
- Day Range
- $1.03–1.10
- 52-Week Range
- $0.79–6.10
- Bid/Ask
- $1.06 / $1.07
- Market Cap
- $6.51 Mil
- Volume/Avg
- 12,827 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 35.57
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- < 0.01%
Company Profile
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 46
- Website
- https://www.ainos.com
Valuation
Metric
|
AIMD
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.20 |
Price/Sales | 35.57 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
AIMD
|
---|---|
Quick Ratio | 1.41 |
Current Ratio | 1.85 |
Interest Coverage | −94.50 |
Quick Ratio
AIMD
Profitability
Metric
|
AIMD
|
---|---|
Return on Assets (Normalized) | −35.95% |
Return on Equity (Normalized) | −41.73% |
Return on Invested Capital (Normalized) | −36.63% |
Return on Assets
AIMD
Medical Devices Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ABT
| Abbott Laboratories | Bsfqkrdq | Qvgyx | $182.6 Bil | |
SYK
| Stryker Corp | Cjvxynnz | Hnqt | $123.6 Bil | |
MDT
| Medtronic PLC | Gkyfsjdtc | Jrqqg | $108.3 Bil | |
BSX
| Boston Scientific Corp | Wdmrqzf | Jxsqhmn | $107.0 Bil | |
EW
| Edwards Lifesciences Corp | Vlmxkfdb | Fbnyk | $51.0 Bil | |
DXCM
| DexCom Inc | Gkrbhwzmqh | Txgb | $50.3 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Szkvnhlgh | Ttvlr | $24.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Jjgscqztz | Cjktyy | $24.3 Bil | |
ALGN
| Align Technology Inc | Zhdjnpwhf | Hclphv | $20.5 Bil | |
PODD
| Insulet Corp | Klpntybkd | Xntrdsv | $12.4 Bil |